- Ideal for antibody stability screening and unfolding analysis
- Allows for rapid characterization of buffer influence on chemical, thermal, colloidal, and conformational stability, long-term storage stability, forced-degradation resistance, as well as biochemical activity and antigen-binding
- Enables quick-and-easy buffer optimization and pre-formulation
- Use with your biophysical or biochemical read-out of choice (e.g. DSF, nanoDSF, DSC, DLS, LC-MS, SEC-HPLC, ELISA, etc.)
- Can just as well be used for stability analysis and buffer optimization of any kind of protein
抗体稳定性筛选和展开分析的理想选择
允许快速表征缓冲液对化学、热、胶体和构象稳定性、长期储存稳定性、抗强制降解性以及生化活性和抗原结合的影响
实现快速简便的缓冲液优化和预配制
与您选择的生物物理或生化读数一起使用（例如 DSF、nanoDSF、DSC、DLS、LC-MS、SEC-HPLC、ELISA 等）
也可用于任何类型蛋白质的稳定性分析和缓冲液优化
Deep-well plate with 96 FDA- and EMA-approved formulations of therapeutic antibodies provided as ready-to-use 5x stock solutions (230 μl each) with a wide range of different buffer compositions (1x at 25 °C):
- pH: 4.6 – 8.0 (acetate, citrate, glycine, histidine, phosphate)
- Salts: 3 – 200 mM (potassium chloride, sodium chloride)
- Amino acids: 1 – 300 mM (glycine, glutamate, methionine, proline)
- Sugars: 12 – 300 mM (maltose, mannitol, sorbitol, sucrose, trehalose)
- Detergents: 0 – 1.6% (polysorbate 20, polysorbate 80)
深孔板含有 96 种 FDA 和 EMA 批准的治疗性抗体制剂，作为即用型 5x 储备溶液（每种 230 μl）提供，具有多种不同的缓冲成分（1x 在 25 °C）：
pH：4.6 – 8.0（醋酸盐、柠檬酸盐、甘氨酸、组氨酸、磷酸盐）
盐：3 – 200 mM（氯化钾、氯化钠）
氨基酸：1 – 300 mM（甘氨酸、谷氨酸、蛋氨酸、脯氨酸）
糖：12 – 300 mM（麦芽糖、甘露醇、山梨糖醇、蔗糖、海藻糖）
洗涤剂：0 – 1.6%（聚山梨醇酯 20、聚山梨醇酯 80）
The FORMOscreen® buffers are formulated using high-purity chemicals and ultrapure water (>18.0 MΩ) and are sterile-filtered using 0.22 μm filters. No preservatives are added. Prepared at room temperature. Please note that the storage buffer of the target antibody or protein may affect the final pH and/or buffer composition of the buffers. It is thus recommended to work with highly-concentration target antibody or protein stock solutions in order to generate a maximum dilution effect when diluting the target antibody or protein into the buffers.
FORMOscreen® 缓冲液使用高纯度化学品和超纯水 (>18.0 MΩ) 配制而成，并使用 0.22 μm 过滤器进行无菌过滤。 不添加防腐剂。 在室温下制备。 请注意，目标抗体或蛋白质的储存缓冲液可能会影响缓冲液的最终 pH 值和/或缓冲液组成。 因此，建议使用高浓度的目标抗体或蛋白质储备溶液，以便在将目标抗体或蛋白质稀释到缓冲液中时产生最大的稀释效果。
Protocol:
Before using the plate, check the seal for any defects.
1) Let the plate adjust to room temperature.
2) Centrifuge the plate at 300 g for 60 seconds.
3) Carefully remove seal and avoid spilling buffers into adjacent wells.
4) Check all wells for possible precipitations.
In case of visible precipitates, carefully resuspend the respective buffers by pipetting up and down. Buffers in rows G and H and buffer A12 can be more susceptible to precipitation. Ensure proper resuspension before using. In case a 5x-stock solution of a buffer cannot be resuspended completely, dilution of the buffer to its final 1x concentration will ensure proper solving of buffer components. This does not impair buffer quality and the buffer can still be used normally.
5) Prepare the assay samples by diluting your target antibody or protein to the final required assay concentration while also bringing the buffers to 1x final concentration.
Example: Antibody stock concentration 8 mg/mL, required antibody assay concentration 1 mg/mL, final assay volume of 50 μL:
– Mix 10 μL of each 5x buffer stock with 33.75 μL ultrapure water
– Add 6.25 μL antibody
– The antibody will then be at 1 mg/mL in the final 1x buffer
6) Alternatively, in order to generate 1x buffer solutions, dilute the 5x stocks 1:5 in ultrapure water, e.g. mix 100 μl of 5x stocks with 400 μl ultrapure water and mix carefully to get 500 μl 1x buffer solutions.
协议：
在使用板之前，请检查密封是否有任何缺陷。
1）让盘子调整到室温。
2) 将板以 300 g 离心 60 秒。
3) 小心取下密封，避免将缓冲液溢出到相邻的孔中。
4) 检查所有孔是否有可能的沉淀。
如果出现可见沉淀，请通过上下移液小心地重新悬浮相应的缓冲液。 G 行和 H 行中的缓冲液以及缓冲液 A12 可能更容易受到沉淀的影响。使用前确保适当的再悬浮。如果缓冲液的 5x 储备溶液不能完全重新悬浮，将缓冲液稀释至最终 1x 浓度将确保缓冲液组分的正确溶解。这不会影响缓冲液质量，缓冲液仍可正常使用。
5) 通过将目标抗体或蛋白质稀释至最终所需的检测浓度来制备检测样品，同时使缓冲液达到最终浓度的 1 倍。
示例：抗体储备浓度 8 mg/mL，所需抗体测定浓度 1 mg/mL，最终测定体积 50 μL：
– 将 10 μL 的每个 5x 缓冲液与 33.75 μL 超纯水混合
– 添加 6.25 μL 抗体
– 最终 1x 缓冲液中的抗体浓度为 1 mg/mL
6) 或者，为了生成 1x 缓冲溶液，在超纯水中以 1:5 稀释 5x 库存，例如将 100 μl 的 5x 原液与 400 μl 超纯水混合，并仔细混合以获得 500 μl 1x 缓冲溶液。
Usage of the FORMOscreen® could give rise to liability for patent infringement, because the use of the provided buffers with their corresponding original product/antibody as listed below is protected by patents. Purchase of the FORMOscreen® grants no right for use of these antibodies with the supplied patent-protected buffers.
使用 FORMOscreen® 可能会导致专利侵权责任，因为使用提供的缓冲液及其相应的原始产品/抗体如下所列受专利保护。 购买 FORMOscreen® 不授予将这些抗体与所提供的受专利保护的缓冲液一起使用的权利。
A1: Actemra/Tocilizumab
A2: Adcetris/Brentuximab Vedotin
A3: Aimovig/Erenumab-Aooe
A4: Amjevita/Adalimumab-Atto
A5: Anthim/Obiltoxaximab
A6: Arzerra/Ofatumumab
A7: Avastin/Bevacizumab
A8: Arcalyst/Rilonacept
A9: Benlysta/Belimumab
A10: Besponsa/Inotuzumab Ozogamicin
A11: Eylea/Aflibercept
A12: Bexxar/Tositumomab
B1: Ajovy/Fremanezumab-Vfrm
B2: Blincyto/Blinatumomab
B3: Campath/Alemtuzumab
B4: Cimzia/Certolizumab Pegol
B5: Evenity/Romosozumab-Aqqg
B6: Cinqair/Reslizumab
B7: Cosentyx/Secukinumab
B8: Crysvita/Burosumab-Twza
B9: Cyltezo/Adalimumab-Adbm
B10: Cyramza/Ramucirumab
B11: Dupixent/Dupilumab
B12: Empliciti/Elotuzumab
C1: Enbrel/Etanercept
C2: Entyvio/Vedolizumab
C3: Erbitux/Cetuximab
C4: Fasenra/Benralizumab
C5: Hemlibra/Emicizumab-Kxwh
C6: Herceptin/Trastuzumab
C7: Cablivi/Caplacizumab-Yhdp
C8: Erelzi/Etanercept-Szzs
C9: Emgality/Galcanezumab-Gnlm
C10: Ilaris/Canakinumab
C11: Ilumya/Tildrakizumab-Asmn
C12: Imfinzi/Durvalumab
D1: Inflectra/Infliximab-Dyyb
D2: Ixifi/Infliximab-Qbtx
D3: Kadcyla/Ado-Trastuzumab Emtansine
D4: Kevzara/Sarilumab
D5: Keytruda/Pembrolizumab
D6: Lemtrada/Alemtuzumab
D7: Mvasi/Bevacizumab-Awwb
D8: Gamifant/Emapalumab-Lzsg
D9: Skyrizi/Risankizumab-Rzaa
D10: Libtayo/Cemiplimab-Rwlc
D11: Ocrevus/Ocrelizumab
D12: Ogivri/Trastuzumab-Dkst
E1: Trazimera/Trastuzumab-Qyyp
E2: Praluent/Alirocumab
E3: Praluent/Alirocumab
E4: Praxbind/Idarucizumab
E5: Takhzyro/Lanadelumab
E6: Prostascint/Capromab Pendetide
E7: Prostascint/Capromab Pendetide
E8: Raptiva/Efalizumab
E9: Raxibacumab/Raxibacumab
E10: Remicade/Infliximab
E11: Renflexis/Infliximab-Abda
E12: Reopro/Abciximab
F1: Repatha/Evolocumab
F2: Repatha/Evolocumab
F3: Rituxan/Rituximab
F4: Siliq/Brodalumab
F5: Simponi/Golimumab
F6: Simponi Aria/Golimumab
F7: Soliris/Eculizumab
F8: Stelara/Ustekinumab
F9: Stelara/Ustekinumab
F10: Synagis/Palivizumab
F11: Taltz/Ixekizumab
F12: Ultomiris/Ravulizumab-Cwvz
G1: Tremfya/Guselkumab
G2: Trogarzo/Ibalizumab-Uiyk
G3: Tysabri/Natalizumab
G4: Unituxin/Dinutuximab
G5: Vectibix/Panitumumab
G6: Xgeva/Denosumab
G7: Xgeva/Denosumab
G8: Cosentyx/Secukinumab
G9: Darzalex/Daratumumab
G10: Gazyva/Obinutuzumab
G11: Humira/Adalimumab
G12: Lartruvo/Olaratumab
H1: Lucentis/Ranibizumab
H2: Opdivo/Nivolumab
H3: Portrazza/Necitumumab
H4: Poteligeo/Mogamulizumab-Kpkc
H5: Simulect/Basiliximab
H6: Sylvant/Siltuximab
H7: Xolair/Omalizumab
H8: Yervoy/Ipilimumab
H9: Zenapax/Daclizumab
H10: Nulojix/Belatacept
H11: Zinbryta/Daclizumab
H12: Zinplava/Bezlotoxumab
Q: Why do I have to resuspend the buffers before use?
A: The plate provides high-concentration buffer stocks (5x) in order to enable a variety of measurements for the customer. Due to the high stock concentration, some components may precipitate over time. In order to avoid inaccuracy during measurements, resuspend the 5x buffer stock solutions by pipetting up and down. After proper resuspension, there are no negative effects from any precipitates.
Q: How many samples can be analyzed with one plate?
A: Depending on the applied analysis method, the plate can serve for many experiments. The plate contains 230 μl of 5x stock solutions, so theoretically 1.15 ml of 1x buffers can be prepared.
Q: Is it possible to purchase individual buffers?
A: Yes, individual buffers can be purchased. Please contact us
